Skip to content
AiSeekAiSeek
Sign in

Company

Ono Pharmaceutical

FollowOpen structure mapAsk about thisResearch this company

Description

Headquarters
JP

Structure of Ono Pharmaceutical

Ono Pharmaceutical

Company

2 connections
PeersCompetition and partners
Relationship began2026
Ono PharmaceuticalCompany · 2 connections
Layer 1

PeersCompetition and partners2

Place in the network

No. 2084 of 15437top 14%

2 direct links

In a group of 11 closely linked entities, around

BiohavenOno PharmaMediar TherapeuticsMoDE pan IgG degraders

New links this week

Weighted by public relations with evidence, recomputed daily.

Relations

Arrows show the direction of the relationship. Filter to focus on a business area.

  • Mediar Therapeuticspartners with →Ono Pharmaceutical
    Company · Mediar TherapeuticsEvidence 1
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-10-07 19:08
      Mediar is also progressing novel fibro-inflammatory targets as part of a recently announced collaboration with Ono Pharmaceutical.
      View source
  • Biohavenagreement with →Ono Pharmaceutical
    Company · BiohavenEvidence 1
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-10-08 16:00
      Biohaven Ltd. together with its wholly owned subsidiaries, ("Biohaven") (NYSE: BHVN) today announced that it has entered into a strategic licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd. ("Ono") (TYO: 4528)
      View source
  • Biohavenpartners with →Ono Pharmaceutical
    Company · BiohavenEvidence 1
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-10-08 16:00
      it has entered into a strategic licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd.
      View source

Showing 1 to 3 of 3

Claims

Read the assertion alongside its sources. Expand a row to inspect the evidence.

FactEvidence 1
agreement withBiohaven

Biohaven Ltd. together with its wholly owned subsidiaries, ("Biohaven") (NYSE: BHVN) today announced that it has entered into a strategic licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd. ("Ono") (TYO: 4528)

PR Newswire news releases · 2026-10-08 16:00

View evidence
  • CompanyPR Newswire news releases2026-10-08 16:00
    Biohaven Ltd. together with its wholly owned subsidiaries, ("Biohaven") (NYSE: BHVN) today announced that it has entered into a strategic licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd. ("Ono") (TYO: 4528)
    View source
FactEvidence 1
partners withBiohaven

it has entered into a strategic licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd.

PR Newswire news releases · 2026-10-08 16:00

View evidence
  • CompanyPR Newswire news releases2026-10-08 16:00
    it has entered into a strategic licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd.
    View source
FactEvidence 1
partners withMediar Therapeutics

Mediar is also progressing novel fibro-inflammatory targets as part of a recently announced collaboration with Ono Pharmaceutical.

PR Newswire news releases · 2026-10-07 19:08

View evidence
  • CompanyPR Newswire news releases2026-10-07 19:08
    Mediar is also progressing novel fibro-inflammatory targets as part of a recently announced collaboration with Ono Pharmaceutical.
    View source

Showing 1 to 3 of 3

Market and valuation

Valuation data is available on Pro and Research.

Included in Pro

Not available: Company signals · Financials · Filings · Guidance